Zacks Research Issues Negative Estimate for TMO Earnings

Key Points

• Zacks Research has lowered its Q3 2025 earnings estimate for Thermo Fisher Scientific to $5.51 per share, down from a previous estimate of $5.52.
• The company's latest earnings report showed a revenue of $10.86 billion for the recent quarter, exceeding analyst expectations of $10.68 billion.
• Analyst price targets for Thermo Fisher Scientific have varied, with Argus reducing their target from $620 to $470, while Goldman Sachs maintains a target of $610.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Zacks Research dropped their Q3 2025 earnings estimates for shares of Thermo Fisher Scientific in a report released on Wednesday, August 13th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $5.51 per share for the quarter, down from their previous estimate of $5.52. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q4 2025 earnings at $6.47 EPS, FY2025 earnings at $22.48 EPS, Q1 2026 earnings at $5.51 EPS, Q3 2026 earnings at $6.19 EPS, Q4 2026 earnings at $6.50 EPS and Q2 2027 earnings at $7.10 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 EPS. The business's quarterly revenue was up 2.9% on a year-over-year basis.

Several other research analysts have also recently commented on TMO. Argus decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Royal Bank Of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Up 1.0%

TMO stock traded up $4.92 during trading on Thursday, reaching $489.96. The stock had a trading volume of 2,462,453 shares, compared to its average volume of 3,069,315. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88. The firm has a fifty day moving average price of $434.83 and a 200 day moving average price of $460.05. The company has a market capitalization of $185.01 billion, a P/E ratio of 28.34, a PEG ratio of 2.61 and a beta of 0.74.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company's stock valued at $13,700,154,000 after purchasing an additional 309,207 shares during the period. Capital World Investors grew its stake in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after acquiring an additional 104,343 shares during the period. Norges Bank bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $2,264,615,000. Franklin Resources Inc. grew its stake in shares of Thermo Fisher Scientific by 11.3% during the 2nd quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company's stock valued at $1,985,759,000 after acquiring an additional 498,238 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Thermo Fisher Scientific by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after acquiring an additional 455,004 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.